Adeona's Planned Clinical Trial of Proprietary Zinc-Based Therapy in Lou Gehrig's Disease is Hot Topic at 2011 California ALS Resea... ( ANN ARBOR Mich. Sept. 30 2011 /- Adeo...)

HOME >> MEDICINE >> TECHNOLOGY

Adeona's Planned Clinical Trial of Proprietary Zinc-Based Therapy in Lou Gehrig's Disease is Hot Topic at 2011 California ALS Research Summit

Date:9/30/2011

ANN ARBOR, Mich., Sept. 30, 2011 /PRNewswire/ -- Adeona Pharmaceuticals, Inc. (NYSE Amex: AEN), a developer of innovative medicines for serious central nervous system diseases, announced today that its planned clinical trial of the Company's proprietary zinc-based therapy for patients suffering from amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's Disease, will be featured during the Hot Topics session at the 2011 California ALS Research Summit (ALS Summit) on Saturday, October 1, 2011. Todd D. Levine, M.D., President of PNA Center for Neurological Research (PNA), Assistant Clinical Professor at the University of Arizona, Co-Director of the Banner Samaritan ALS Center in Phoenix, Arizona and Lead Principal Investigator of the planned clinical trial will present the potential benefits of zinc therapy for ALS patients. Dr. Levine will also discuss preliminary data from PNA's ongoing Phase I/II open label safety study of zinc therapy in ALS patients at the ALS Summit.

"I am very excited to present our theories on the potential role of zinc in the treatment of ALS. We believe that by giving high doses of zinc to ALS patients, we can decrease the amount of toxicity from unbound glutamate and prevent neurotoxicity," said Dr. Levine. "Our goal is to improve the quality of life of patients with ALS by slowing the progression of this devastating disease."

About Amyotrophic Lateral Sclerosis (ALS)

ALS is a devastating progressive neurodegenerative disease that affects the nerve cells in the brain and the spinal cord in people of all ages and both sexes. It is estimated that as many as 30,000 Americans may have the disease at any given time. The progressive degeneration of the motor neurons in ALS eventually leads to the death of the patient. Motor neurons reach from the brain to the spinal cord and from the spinal cord to the muscles throughout the bo
'/>"/>

SOURCE Adeona Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5
Related medicine technology :

1. Plavix(R) Indications Expanded in Japan to Include Patients with Acute Coronary Syndrome for Whom Percutaneous Coronary Intervention Is Being Planned
2. TargeGen Announces Planned Initiation of Clinical Trial of JAK2 Inhibitor TG101348 in Myeloproliferative Disease Patients, and Presentations at ASH
3. Encorium Announces the Initiation of a Strategic Partnership With Prologue Research After the Postponement of Negotiations Regarding Its Planned Acquisition; Strategic Reorganization and Cost Reduction Plan Initiated as Strategic Alternatives are Investig
4. Vical Receives Milestone Payment from Merck & Co., Inc. Triggered by Planned Initiation of Investigational Cancer DNA Vaccine Trial
5. Celtic Pharma Announces Update on Status of XERECEPT(R) Program Sale Planned in 2009
6. Hana Biosciences Announces Successful Planned Independent Safety Analysis Supports Ability to Complete Pivotal rALLy Clinical Trial of Marqibo, Its Lead Novel Anti-Cancer Compound
7. US FDA Approves Extavia(R) - the First in a New Portfolio of Planned MS Therapies from Novartis to Help Patients with this Devastating Disease
8. Anthera Pharmaceuticals Announces Agreement With the FDA on a SPA for Planned Phase 3 Varespladib A-002 Study; Daniel K. Spiegelman Joins Board of Directors
9. Xanodyne Announces Planned President & CEO Succession
10. Breast Cancer Patient First in Latin America to Receive Treatment Using Elekta VMAT Planned with Monaco Software
11. Phase 3 Trial of Aflibercept in Second-Line Metastatic Colorectal Cancer to Continue as Planned at Recommendation of Independent Data Monitoring Committee

Post Your Comments:

(Date:5/23/2013)... BioElectronics Corporation (OTC Pink: BIEL), the maker of ... FDA panel meeting for non-thermal shortwave diathermy: ... Therapy Meeting was held on May 21, 2013 in ... of the meeting was very narrow, in that the ... the application of non-thermal shortwave diathermy for the treatment ...

(Date:5/23/2013)... Conn. , May 23, 2013 CAS Medical Systems, ... medical devices for non-invasive patient monitoring, today announced that ... Officer, will present at the 2 nd Annual Marcum ... Hyatt Hotel in New York City . ... p.m. ET in the Estate 10 room and will be ...

(Date:5/23/2013)... , May 23, 2013 Halozyme ... announced the appointment of David A. ... Ramsay was most recently Vice President, Corporate Development ... ) "With his established financial management ... gained by working in our commercial group for ...

Breaking Medicine Technology:BioElectronics and Pulsed Shortwave Therapy Make Progress 2 CASMED to Present at the 2nd Annual Marcum MicroCap Conference 2 Halozyme Therapeutics Names David A. Ramsay Chief Financial Officer 2

[0] BioElectronics and Pulsed Shortwave Therapy Make Progress [0] CASMED to Present at the 2nd Annual Marcum MicroCap Conference [0] Halozyme Therapeutics Names David A. Ramsay Chief Financial Officer

... May 21 Isis Pharmaceuticals, Inc. (Nasdaq: ISIS ), the leader ... Citi Investment Research,s 2010 Global Health Care Conference on Thursday, May 27, ... Hotel. , , , ... the presentation will be available on the "Investors & Media" section of the ...

... Sorrento Therapeutics, Inc. (OTC Bulletin Board: SRNE) ... Small Business Technology Transfer Research (STTR) grant from the ... grant was awarded to support the Company,s program to ... combat Staphylococcus aureus ( S. aureus ...

Cached Medicine Technology:Isis Pharmaceuticals to Present at the 2010 Citi Investment Research Global Health Care Conference 2 Sorrento Therapeutics Awarded NIH Grant for MRSA Program 2 Sorrento Therapeutics Awarded NIH Grant for MRSA Program 3 Sorrento Therapeutics Awarded NIH Grant for MRSA Program 4

Isis Pharmaceuticals to Present at the 2010 Citi Investment Research Global Health Care Conference Sorrento Therapeutics Awarded NIH Grant for MRSA Program

(Date:5/23/2013)... FL (PRWEB) May 23, 2013 ... regenerative medicine company focused on the commercialization of ... and regeneration, today announced that the Company and ... million grant, for which AxoGen’s portion is approximately ... administrated by the U.S. Department of Defense (DoD) ...

(Date:5/23/2013)... 2013 Hile Design LLC is pleased ... awarded a Silver Creative Award at the Summit International ... entry was for its “Open Doors” animation promoting Scio ... in the 2013 District 6 ADDY Awards for the ... Creative Award recognizes and celebrates the creative achievements of ...

(Date:5/23/2013)... Utah (PRWEB) May 23, 2013 Registered ... R.D., published an article today on Tatalou.com offering helpful ... vacation. , The article, titled “ How to Stay ... important to carry hand sanitizer, when it’s safe to ... out for seafood, the importance of staying hydrated and ...

(Date:5/23/2013)... OH and Durham, NC (PRWEB) May 23, 2013 ... and commercialization firm that funds and develops innovative ... Deep Brain Innovations, LLC (DBI). DBI will ... optimize deep brain stimulation (DBS) therapy for patients ... is effective in treating Parkinson’s disease and generates ...

(Date:5/23/2013)... Consortium, Ltd., issued the following statement today on ... Reform of chemical safety legislation will succeed only ... Ensuring the safety and appropriate use of chemicals ... Toxic Substances Control Act is a critical opportunity ... transforming toxicity testing "from a system based on ...

Breaking Medicine News(10 mins):Health News:AxoGen, Inc. Receives Grant in Partnership with Vanderbilt University from U.S. Department of Defense 2 Health News:AxoGen, Inc. Receives Grant in Partnership with Vanderbilt University from U.S. Department of Defense 3 Health News:How to Stay Healthy While Traveling 2 Health News:NDI Launches Deep Brain Innovations, LLC 2 Health News:NDI Launches Deep Brain Innovations, LLC 3

[0] AxoGen, Inc. Receives Grant in Partnership with Vanderbilt University from U.S. Department of Defense [0] Hile Design Wins Silver Creative Award at the 2013 Summit Internationals [0] How to Stay Healthy While Traveling [0] NDI Launches Deep Brain Innovations, LLC [0] Chemical Safety Improvement Act of 2013: PETA International Science Consortium

... global research,organization, announced that it has appointed new staff ... Resourcing Solutions,division. Maria Sanchez Garcia will lead the group ... whilst Hannah King joins our United,Kingdom team to focus ... very pleased to help in the continued growth of ...

... deal demonstrates commitment to dermatology and innovation, ... Stiefel Laboratories, Inc.,the world,s largest independent pharmaceutical ... has completed its previously announced,acquisition of Princeton, ... of the acquisition, all remaining outstanding shares ...

... Call and Webcast Scheduled for August 7, 2008 ... Aug. 6 The Ensign,Group, Inc. (Nasdaq: ... group of,skilled nursing, rehabilitative care services and assisted ... quarter of fiscal,year 2008., (Logo: http://www.newscom.com/cgi-bin/prnh/20071213/LATH168LOGO ...

... ... Diluted FAD ... Second Quarter Investments $250 Million, NEWPORT BEACH, Calif., ... operations,and investment activity for the second quarter and the six months ended,June 30, 2008., ...

... put themselves at increased risk for second malignancies , , ... British adults who survived childhood cancers currently smoke, while ... in their lives, a new study reports. , ... cancer have a greater chance of developing cardiovascular disease, ...

... Aug. 6 AMN Healthcare Services,Inc. (NYSE: AHS ... leader in all of its business segments today reported ... quarter last year and a 7%,increase from last quarter. ... Nurse & Allied, Locum Tenens and,Physician Permanent Placement, experienced ...

Chiltern's Resourcing Solutions Division Appoints New Managers to Spain and the United Kingdom Stiefel Laboratories Completes Acquisition of Barrier Therapeutics The Ensign Group, Inc. Reports Second Quarter 2008 Earnings of $.32 per Diluted Share and Raises 2008 Guidance NHP Reports Second Quarter 2008 Earnings One-Fifth of British Childhood Cancer Survivors Smoke AMN Healthcare Reports Second Quarter 2008 Results

... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...

... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...

... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...

Medicine Products:

Lyme Antibodies, Total (CSF)Luteinizing Hormone, Pooled Lupus Anticoagulant Panel with Reflex to 1:1 Mixes & Confirmations Lupus Erythematous, Tissue